Serving the Society Since 1986
高级搜索
Volume 35 Issue 6
December 2020

    Wen-Hua Kong, Rong Zhao, Jun-Bo Zhou, Fang Wang, De-Guang Kong, Jian-Bin Sun, Qiong-Fang Ruan and Man-Qing Liu. Serologic Response to SARS-CoV-2 in COVID-19 Patients with Different Severity[J]. Virologica Sinica, 2020, 35(6): 752-757. doi: 10.1007/s12250-020-00270-x
    Citation: Wen-Hua Kong, Rong Zhao, Jun-Bo Zhou, Fang Wang, De-Guang Kong, Jian-Bin Sun, Qiong-Fang Ruan, Man-Qing Liu. Serologic Response to SARS-CoV-2 in COVID-19 Patients with Different Severity .VIROLOGICA SINICA, 2020, 35(6) : 752-757.  http://dx.doi.org/10.1007/s12250-020-00270-x
    shu

    不同临床分型的新型冠状病毒病例中的新冠病毒血清学反应

    cstr: 32224.14.s12250-020-00270-x
    • 1.

      武汉市疾病预防控制中心

    • 2.

      武汉市第三医院

    • 通讯作者： 刘满清, liumq33@hotmail.com, ORCID: 0000-0002-9754-3102
    • 收稿日期： 2020-05-31
      录用日期： 2020-07-07
      出版日期： 2020-07-23
    • 新冠肺炎（COVID-19）在全球的快速扩散和大流行，要求我们更加深入地认识该疾病的免疫学特征，包括基本免疫指标出现的时序。本研究纳入了88名来自武汉的新冠病例，其确诊时间为2020年一至二月，包括32名临床分型为重型/危重型的病例和56名轻型/普通型病例。病例平均年龄56.43岁、年龄范围17至83岁、男女性别比为43:45。我们使用商用试剂检测了病例呼吸道标本的新冠病毒核酸，使用磁微粒化学发光法检测了其血样中的新冠IgM和IgG抗体水平，并分析其与疾病严重程度的相关性。血清学与核酸联合检测在88名病例中确认了84名新冠感染阳性者，阳性率为95.45%，显著高于单纯核酸检测（73.86%）或单纯血清学检测（65.91%）（P < 0.001）。我们进一步分析了新冠抗体反应的时间顺序，结果显示血清抗体转换始于症状出现后的第五天，且IgG抗体出现早于IgM。对不同临床分型病例的比较显示较早的血清抗体转换和高抗体水平可能与较轻的临床症状有关。以上结果支持在常规新冠感染诊断中应用血清-核酸联合检测，同时也为理解不同临床分型病例间抗体反应的差别提供了证据。

    Serologic Response to SARS-CoV-2 in COVID-19 Patients with Different Severity

    • 1.

      Wuhan Center for Disease Control and Prevention, Wuhan 430024, China

    • 2.

      Wuhan Third Hospital, Tongren Hospital of Wuhan University, Wuhan 430060, China

    • Corresponding author: Man-Qing Liu, liumq33@hotmail.com
    • ORCID: 0000-0002-9754-3102
    • Received Date: 31 May 2020
      Accepted Date: 07 July 2020
      Published Date: 23 July 2020
    • The immense patient number caused by coronavirus disease 2019 (COVID-19) global pandemic brings the urge for more knowledge about its immunological features, including the profile of basic immune parameters. In this study, eighty-eight reported COVID-19 patients in Wuhan were recruited from January to February, 2020, including 32 severe/critical cases and 56 mild/moderate cases. Their mean age was 56.43 years (range 17-83) and gender ratio (male/female) was 43:45. We tested SARS-CoV-2 RNA with commercial kits, investigated the level of serologic IgM and IgG antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) using magnetic particle chemiluminescence immunoassays, and compared the results of serologic tests and nucleic acid test (NAT). Among 88 patients, 95.45% were confirmed as positive by the combination of NAT and antibody test, which was significantly higher (P < 0.001) than by single nucleic acid test (73.86%) or serologic test (65.91%). Then the correlation between temporal profile and the level of antibody response was analyzed. It showed that seroconversion started on day 5 after disease onset and IgG level was rose earlier than IgM. Comparison between patients with different disease severity suggested early seroconversion and high antibody titer were linked with less severe clinical symptoms. These results supported the combination of serologic testing and NAT in routine COVID-19 diagnosis and provided evidence on the temporal profile of antibody response in patients with different disease severity.
    • 加载中

      1. Cereda D, Tirani M, Rovida F, Demicheli V, Ajelli M, Poletti P, Trentini F, Guzzetta G, Marziano V, Barone A, Magoni M, Deandrea S, Diurno G, Lombardo M, Faccini M, Pan A, Bruno R, Pariani E, Grasselli G, Piatti A, Gramegna M, Baldanti F, Melegaro A, Merler S (2020) The early phase of the COVID-19 outbreak in Lombardy, Italy. arXiv: 2003.09320

      2. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y, Xia J, Yu T, Zhang X, Zhang L (2020) Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 395:507-513
          doi: 10.1016/S0140-6736(20)30211-7

      3. Dong C, Ni L, Ye F, Chen ML, Feng Y, Deng YQ, Zhao H, Wei P, Ge J, Li X, Sun L, Wang P, Liang P, Guo H, Wang X, Qin CF, Chen F (2020) Characterization of anti-viral immunity in recovered individuals infected by SARS-CoV-2. medRxiv 2020.03.17.20036640

      4. Epidemiology Working Group for NCIP Epidemic Response, Chinese Center for Disease Control and Prevention (2020) The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China. Zhonghua Liu Xing Bing Xue Za Zhi 41:145-151

      5. Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A, Cereda D, Coluccello A, Foti G, Fumagalli R et al (2020) Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy region, Italy. JAMA 323: 1574-1581

      6. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B (2020) Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395:497-506
          doi: 10.1016/S0140-6736(20)30183-5

      7. Lauer SA, Grantz KH, Bi Q, Jones FK, Zheng Q, Meredith HR, Azman AS, Reich NG, Lessler J (2020) The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 172:577-582
          doi: 10.7326/M20-0504

      8. Loeffelholz MJ, Tang YW (2020) Laboratory diagnosis of emerging human coronavirus infections-the state of the art. Emerg Microbes Infect 9:747-756
          doi: 10.1080/22221751.2020.1745095

      9. Long QX, Liu BZ, Deng HJ, Wu GC, Deng K, Chen YK, Liao P, Qiu JF, Lin Y, Cai XF, Wang DQ, Hu Y, Ren JH, Tang N, Xu YY, Yu LH, Mo Z, Gong F, Zhang XL, Tian WG, Hu L, Zhang XX, Xiang JL, Du HX, Liu HW, Lang CH, Luo XH, Wu SB, Cui XP, Zhou Z, Zhu MM, Wang J, Xue CJ, Li XF, Wang L, Li ZJ, Wang K, Niu CC, Yang QJ, Tang XJ, Zhang Y, Liu XM, Li JJ, Zhang DC, Zhang F, Liu P, Yuan J, Li Q, Hu JL, Chen J, Huang AL (2020) Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat Med 26:845-848
          doi: 10.1038/s41591-020-0897-1

      10. National Health Commission of the People's Republic of China (2020a) The diagnosis and treatment plan of the novel coronavirus-infected pneumonia, 3rd edn

      11. National Health Commission of the People's Republic of China (2020b) The prevention and control plan of new coronavirus pneumonia, 3rd edn

      12. Okba NMA, Müller MA, Li W, Wang C, GeurtsvanKessel CH, Corman VM, Lamers MM, Sikkema RS, de Bruin E, Chandler FD, Yazdanpanah Y, Le Hingrat Q, Descamps D, Houhou-Fidouh N, Reusken CBEM, Bosch BJ, Drosten C, Koopmans MPG, Haagmans BL (2020) Severe acute respiratory syndrome coronavirus 2-specific antibody responses in coronavirus disease patients. Emerg Infect Dis 26:1478-1488
          doi: 10.3201/eid2607.200841

      13. Pan A, Liu L, Wang C, Guo H, Hao X, Wang Q, Huang J, He N, Yu H, Lin X, Wei S, Wu T (2020) Association of public health interventions with the epidemiology of the COVID-19 outbreak in Wuhan, China. JAMA 323:1-9

      14. Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, and the Northwell COVID-19 Research Consortium, Barnaby DP, Becker LB, Chelico JD, Cohen SL, Cookingham J, Coppa K, Diefenbach MA, Dominello AJ, Duer-Hefele J, Falzon L, Gitlin J, Hajizadeh N, Harvin TG, Hirschwerk DA, Kim EJ, Kozel ZM, Marrast LM, Mogavero JN, Osorio GA, Qiu M, Zanos TP (2020) Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York city area. JAMA 323:2052-2059
          doi: 10.1001/jama.2020.6775

      15. Shi Y, Wang Y, Shao C, Huang J, Gan J, Huang X, Bucci E, Piacentini M, Ippolito G, Melino G (2020) COVID-19 infection: the perspectives on immune responses. Version 2. Cell Death Differ 27:1451-1454
          doi: 10.1038/s41418-020-0530-3

      16. Thevarajan I, Nguyen THO, Koutsakos M, Druce J, Caly L, van de Sandt CE, Jia X, Nicholson S, Catton M, Cowie B, Tong SYC, Lewin SR, Kedzierska K (2020) Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19. Nat Med 26:453-455
          doi: 10.1038/s41591-020-0819-2

      17. To KK, Tsang OT, Leung WS, Tam AR, Wu TC, Lung DC, Yip CC, Cai JP, Chan JM, Chik TS, Lau DP, Choi CY, Chen LL, Chan WM, Chan KH, Ip JD, Ng AC, Poon RW, Luo CT, Cheng VC, Chan JF, Hung IF, Chen Z, Chen H, Yuen KY (2020) Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. Lancet Infect Dis 20:565-574
          doi: 10.1016/S1473-3099(20)30196-1

      18. World Health Organization (2020) Coronavirus disease 2019 (Covid-19) situation reports

      19. Wu Z, McGoogan JM (2020) Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA. https://doi.org/10.1001/jama.2020.2648

      20. Wu F, Wang A, Liu M, Wang Q, Chen J, Xia S, Ling Y, Zhang Y, Xun J, Lu L, Jiang S, Lu H, Wen Y, Huang J (2020) Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications. medRxiv 2020.03.30.20047365

      21. Xiang F, Wang X, He X, Peng Z, Yang B, Zhang J, Zhou Q, Ye H, Ma Y, Li H, Wei X, Cai P, Ma WL (2020) Antibody detection and dynamic characteristics in patients with COVID-19. Clin Infect Dis 2020:ciaa461

      22. Zhang W, Du RH, Li B, Zheng XS, Yang XL, Hu B, Wang YY, Xiao GF, Yan B, Shi ZL, Zhou P (2020) Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes. Emerg Microbes Infect 9:386-389
          doi: 10.1080/22221751.2020.1729071

      23. Zhao J, Yuan Q, Wang H, Liu W, Liao X, Su Y, Wang X, Yuan J, Li T, Li J, Qian S, Hong C, Wang F, Liu Y, Wang Z, He Q, Li Z, He B, Zhang T, Fu Y, Ge S, Liu L, Zhang J, Xia N, Zhang Z (2020a) Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019. Clin Infect Dis 2020:ciaa344

      24. Zhao R, Li M, Song H, Chen J, Ren W, Feng Y, Song JW, Peng Y, Su B, Guo X, Wang Y, Chen J, Li J, Sun H, Bai Z, Cao WJ, Zhu J, Zhang Q, Sun Y, Sun S, Mao X, Su J, Chen H, He A, Jin R, Sun L (2020b) Serological diagnostic kit of SARS-CoV-2 antibodies using CHO-expressed full-length SARS-CoV-2 S1 proteins. medRxiv 2020.03.26.20042184

    • 加载中

    Figures(3) / Tables(2)

    PDF

    Article Metrics

    Article views(10744) PDF downloads(26) Cited by(0)

    Related
    Proportional views
      通讯作者: 陈斌, bchen63@163.com
      • 1. 

        沈阳化工大学材料科学与工程学院 沈阳 110142

      1. 本站搜索
      2. 百度学术搜索
      3. 万方数据库搜索
      4. CNKI搜索

      Serologic Response to SARS-CoV-2 in COVID-19 Patients with Different Severity

        Corresponding author: Man-Qing Liu, liumq33@hotmail.com
      • 1. Wuhan Center for Disease Control and Prevention, Wuhan 430024, China
      • 2. Wuhan Third Hospital, Tongren Hospital of Wuhan University, Wuhan 430060, China
      • Received Date: 31 May 2020
      • Accepted Date: 07 July 2020
      • Published Date: 23 July 2020

      Abstract: The immense patient number caused by coronavirus disease 2019 (COVID-19) global pandemic brings the urge for more knowledge about its immunological features, including the profile of basic immune parameters. In this study, eighty-eight reported COVID-19 patients in Wuhan were recruited from January to February, 2020, including 32 severe/critical cases and 56 mild/moderate cases. Their mean age was 56.43 years (range 17-83) and gender ratio (male/female) was 43:45. We tested SARS-CoV-2 RNA with commercial kits, investigated the level of serologic IgM and IgG antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) using magnetic particle chemiluminescence immunoassays, and compared the results of serologic tests and nucleic acid test (NAT). Among 88 patients, 95.45% were confirmed as positive by the combination of NAT and antibody test, which was significantly higher (P < 0.001) than by single nucleic acid test (73.86%) or serologic test (65.91%). Then the correlation between temporal profile and the level of antibody response was analyzed. It showed that seroconversion started on day 5 after disease onset and IgG level was rose earlier than IgM. Comparison between patients with different disease severity suggested early seroconversion and high antibody titer were linked with less severe clinical symptoms. These results supported the combination of serologic testing and NAT in routine COVID-19 diagnosis and provided evidence on the temporal profile of antibody response in patients with different disease severity.

        HTML

      Introduction